Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2005 1
2012 1
2017 2
2019 1
2021 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

8 results
Results by year
Filters applied: . Clear all
Page 1
Discovery of JTZ-951: A HIF Prolyl Hydroxylase Inhibitor for the Treatment of Renal Anemia.
Ogoshi Y, Matsui T, Mitani I, Yokota M, Terashita M, Motoda D, Ueyama K, Hotta T, Ito T, Hase Y, Fukui K, Deai K, Yoshiuchi H, Ito S, Abe H. Ogoshi Y, et al. Among authors: deai k. ACS Med Chem Lett. 2017 Nov 20;8(12):1320-1325. doi: 10.1021/acsmedchemlett.7b00404. eCollection 2017 Dec 14. ACS Med Chem Lett. 2017. PMID: 29259755 Free PMC article.
JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-╬▒ protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor.
Fukui K, Shinozaki Y, Kobayashi H, Deai K, Yoshiuchi H, Matsui T, Matsuo A, Matsushita M, Tanaka T, Nangaku M. Fukui K, et al. Among authors: deai k. Eur J Pharmacol. 2019 Sep 15;859:172532. doi: 10.1016/j.ejphar.2019.172532. Epub 2019 Jul 10. Eur J Pharmacol. 2019. PMID: 31301309
Pharmacological characterization of (3S)-3-(hydroxymethyl)-4-(5-methylpyridin-2-yl)-N-[6-(2,2,2-trifluoroethoxy)pyridin-3-yl]-3,4-dihydro-2H-benzo[b][1,4]oxazine-8-carboxamide (JTS-653), a novel transient receptor potential vanilloid 1 antagonist.
Kitagawa Y, Miyai A, Usui K, Hamada Y, Deai K, Wada M, Koga Y, Sakata M, Hayashi M, Tominaga M, Matsushita M. Kitagawa Y, et al. Among authors: deai k. J Pharmacol Exp Ther. 2012 Aug;342(2):520-8. doi: 10.1124/jpet.112.194027. Epub 2012 May 15. J Pharmacol Exp Ther. 2012. PMID: 22588258